Participant baseline characteristics and mortality
| Characteristic | Value |
|---|---|
| Age, N=371 | 44 (37–51) |
| Female sex | 81/371 (22%) |
| Monthly income*, N=363 | 875 (635–1075) |
| Monthly disposable income*, N=363 | 500 (260–700) |
| Welfare | 261/367 (71%) |
| History of homelessness | 252/370 (68%) |
| Visit with family physician (6 months)† | 311/369 (84%) |
| Mortality | |
| Mortality | 31/371 (8%) |
| Age at death, N=31 | 47 (23–72) |
| Causes of death | |
| Physical disease | 16/31 (52%) |
| Accidental drug overdose | 7/31 (23%) |
| Trauma | 4/31 (13%) |
| Suicide | 2/31 (6%) |
| Undetermined | 2/31 (6%) |
| Mental illness | |
| Psychotic disorder | 175/371 (47%) |
| Mood disorder | 105/371 (28%) |
| Substance dependence | 355/371 (96%) |
| Stimulant dependence | 305/371 (82%) |
| Opioid dependence | 202/371 (54%) |
| Alcohol dependence | 67/371 (18%) |
| Physical illness | |
| HIV exposure | 63/359 (18%) |
| Hepatitis B exposure | 141/349 (40%) |
| Current hepatitis B infection | 5/141 (4%) |
| Hepatitis C exposure | 244/357 (68%) |
| Current hepatitis C infection | 180/244 (74%) |
| HIV/HCV co-infection | 43/244 (18%) |
| Hepatic fibrosis (APRI>0.7)‡ | 73/353 (21%) |
| Substance use§ | |
| Any injection drug use | 194/366 (53%) |
| Composite Harm Score, N=364 | 2806 (1847–4010) |
| Any tobacco use | 336/364 (92%) |
| Any crack cocaine use | 210/364 (58%) |
| Any powder cocaine use | 86/364 (24%) |
| Any cannabis use | 173/364 (48%) |
| Any heroin use | 127/364 (35%) |
| Any methamphetamine use | 91/374 (25%) |
| Any alcohol use | 180/366 (49%) |
| Users sharing crack pipes | 108/207 (52%) |
| Users sharing needles | 3/194 (2%) |
Median and IQR reported for continuous variables. Number and proportion reported for categorical variables.
*Canadian dollars.
†Reported for first 6 months of study follow-up.
‡APRI, surrogate measure of hepatic fibrosis.
§Reported for month prior to baseline.
APRI, aspartate aminotransferase-to-Platelet Ratio Index; HCV, hepatitis C virus.